What research shows about aod-9604 tesamorelin stack dosage, from reported ranges and timing to approval status, side effects, and safety cautions.
There is no formally established AOD-9604 and tesamorelin stack dosage, because no health authority has approved these two peptides for combined human use. Clinical trials of tesamorelin used 1.4 mg to 2 mg injected subcutaneously once daily, while AOD-9604 research typically describes 250 mcg to 500 mcg per day, often split into two doses. Every stack number circulating online is extrapolated from separate studies or from user reports, not from a controlled trial of the combination.
That distinction matters if you are weighing an aod 9604 vs tesamorelin comparison. The two compounds act through different pathways, have different regulatory status, and carry different risk profiles.
Why No Official Stack Dosage Exists
Tesamorelin (sold under the brand name Egrifta) is FDA-approved, but only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is a prescription product with a fixed daily injection regimen, not a number a user can freely scale.
AOD-9604 is a synthetic fragment of human growth hormone, corresponding to amino acids 176 through 191. It has been studied in small human trials for obesity and cartilage repair, but it is not approved by the FDA for any human use.
Because one compound is a prescription drug with a narrow indication and the other is a research chemical with no approved human indication, there is no dosing schedule that regulators or clinical guidelines recognize as a combined stack. Reported numbers are observations, not validated recommendations.
AOD-9604 is not FDA-approved for human use in the United States. Tesamorelin is FDA-approved, but only for HIV-associated lipodystrophy and only by prescription.
AOD-9604 vs Tesamorelin at a Glance
| Feature | AOD-9604 | Tesamorelin |
|---|---|---|
| Regulatory status | Not FDA-approved for human use | FDA-approved for HIV-associated lipodystrophy |
| Mechanism | HGH fragment 176-191 studied for fat metabolism effects | GHRH analog that stimulates endogenous growth hormone |
| Studied or reported dose | 250 mcg to 1 mg per day reported in research summaries | 1.4 mg or 2 mg once daily in trials and on the label |
| Reported half-life | Short, generally under an hour | Longer, with growth hormone and IGF-1 effects lasting through the day |
| Route | Subcutaneous injection | Subcutaneous injection |
| Commonly reported side effects | Injection-site reactions, headache, joint discomfort | Injection-site reactions, joint pain, swelling, elevated IGF-1 |
| Prescription required | No, sold as a research chemical | Yes |
Reported Doses and Timing
AOD-9604 dosing as described in research
Human studies of AOD-9604 used daily doses in the 250 mcg to 1 mg range for limited periods, usually in a fasted state. A typical aod 9604 dosage protocol described in community write-ups lands between 250 mcg and 500 mcg per day, sometimes split into a morning and an evening injection.
Vials labeled with an aod-9604 5mg dosage are simply 5 mg of lyophilized powder. That figure describes total vial content, not a recommended daily amount, and it says nothing about the purity or identity of the peptide inside.
Tesamorelin dosing in clinical trials
The approved regimen is 1.4 mg or 2 mg injected subcutaneously once daily, at roughly the same time each day. Tesamorelin raises endogenous growth hormone, which also raises IGF-1, and IGF-1 monitoring is part of standard clinical follow-up.
Where the Stack Idea Comes From
Stacking language comes mostly from body-composition forums rather than from clinical research. Users often describe an aod 9604 stack that pairs the fragment with growth-hormone-releasing peptides or other compounds marketed for fat loss.
Online discussion of aod-9604 mots-c tesamorelin dosage usually blends two very different categories: a prescription drug with trial data, and research chemicals with limited or no human data. MOTS-c in particular is far less studied than tesamorelin, so any three-compound protocol is speculative by definition.
No published trial has tested AOD-9604, MOTS-c, and tesamorelin together in humans. Anyone presenting an exact combined milligram schedule is describing personal experience or secondhand reports, not evidence.
Safety, Side Effects, and Legal Status
- Tesamorelin is prescription-only in the United States and should be used under a clinician's supervision, with lab monitoring.
- Research-grade AOD-9604 is not regulated as a drug, so purity, sterility, and actual content are not independently guaranteed.
- Combining compounds increases the chance of additive effects such as joint pain, fluid retention, and changes in blood sugar.
- Self-dosing without lab work makes it nearly impossible to tell whether a symptom comes from the peptide, the dose, or an unrelated cause.
Tesamorelin is contraindicated in pregnancy and in people with active malignancy, and it should not be used when the hypothalamic-pituitary axis is disrupted. Buying peptides from unregulated vendors does not guarantee that the vial contains the labeled compound.
Questions to Ask Before Considering Either Peptide
A clinician can review baseline labs, contraindications, and whether any monitored compound is appropriate for your situation. They can also explain why a prescription drug and a research chemical are not interchangeable, even when both are discussed as fat-loss tools.
If you are already using either peptide, tell your healthcare provider and any pharmacist you work with. Peptides can interact with other medications and with conditions such as diabetes, thyroid disease, or a history of cancer.
Key Takeaways
- No official AOD-9604 and tesamorelin stack dosage exists in any clinical guideline.
- Tesamorelin's studied dose is 1.4 mg to 2 mg once daily; reported AOD-9604 research doses are 250 mcg to 500 mcg per day.
- Only tesamorelin is FDA-approved, and only for HIV-associated lipodystrophy.
- Stack protocols found online are anecdotal and untested as combinations.
Frequently Asked Questions
What is the typical AOD-9604 and tesamorelin stack dosage?
There is no official stack dosage, because the combination has never been tested in a controlled human trial. For reference, tesamorelin trials used 1.4 mg to 2 mg injected once daily, and AOD-9604 research commonly describes 250 mcg to 500 mcg per day. Any combined schedule you read online is anecdotal.
Is AOD-9604 or tesamorelin FDA-approved?
Tesamorelin is FDA-approved under the brand name Egrifta, but only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. AOD-9604 is not FDA-approved for any human use and is sold as a research chemical. Neither product is approved for general weight loss.
Can you stack AOD-9604 with tesamorelin safely?
No human trial has evaluated that combination, so its safety profile is unknown. Tesamorelin is a prescription drug that raises IGF-1 and requires medical monitoring, while research-grade AOD-9604 is unregulated and may not contain what the label claims. Anyone considering either peptide should talk with a healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.